Corrosion analysis of NiCu and PdCo thermal seed alloys used as interstitial hyperthermia implants

Ni1‐xCrx alloy for self controlled magnetic hyperthermia

“…Synthesis of magnetic materials that are not affected by alternating magnetic fields above 319 K has become essential in order to prevent over heating of normal cells [3,9]. Iron oxide [10,11], cobalt-palladium [5,12], nickel-copper [12,13], and gadolinium based compounds [14] have been investigated for use in localized hyperthermia treatment of cancer using alternating magnetic field. In this study, the magnetic properties of nickel-chromium alloys for hyperthermia treatment of cancer are investigated for the first time.…”

A smart, phase transitional and injectable DOX/PLGA-Fe implant for magnetic-hyperthermia-induced synergistic tumor eradication

“…Additionally, the cytotoxicity assay for nomal cell in Figure S1 also demonstrated the 16 biocompatible property in nomal tissue. No significant cytotoxicity of PLGA-Fe was observed for cells, but the decline of cell viability of group DOX/PLGA-Fe was owing to the toxicity of DOX for cells.…”

“…Simultaneously, poor corrosion of ferromagnetic thermo seeds requires an additional removal after therapeutic process [16]. Previously, our group had developed an 5 "injectable smart phase-transformation implants" based on polylactic-co-glycolic acid (PLGA) integrating with magnetic material for highly efficient in vivo magnetic hyperthermal therapy of tumor [17].…”

Magneto-mechanical stimulation of bone growth in a bonded array of ferromagnetic fibres

“…The primary requirement is that the fibre material should be ferromagnetic. It has been established [22][23][24][25][26] that several such materials exhibit good corrosion resistance in biological fluids. In fact, it has been shown that (magnetic) ferritic stainless steels display superior resistance to pitting and crevice corrosion, and to the leaching of iron, chromium and nickel, compared with 316 L, the (non-magnetic) stainless steel in common use for implants [26].…”